famotidine has been researched along with Helicobacter Infections in 65 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin for vascular protection." | 9.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 9.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "Two hundred patients with duodenal ulcer were randomly divided into the treated group treated with JWC, 160 mg 3 times per day and the control group treated with famotidine 20 mg twice per day, both by orally taking before meal for 4 weeks, 100 cases in each group." | 9.12 | [Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer]. ( Chen, JX; Chen, JY; Ji, F, 2006) |
| "Omeprazole is more effective than famotidine for the control of gastro-oesophageal reflux disease symptoms in H." | 9.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "The aim of this study was to evaluate the effect of famotidine, a histamine receptor antagonist on corpus gastritis in patients with peptic ulcer disease." | 9.11 | Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. ( Chayama, K; Haruma, K; Hata, J; Ito, M; Kamada, T; Kawamura, Y; Kusunoki, H; Sugiu, K; Tanaka, S, 2005) |
| "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine." | 9.09 | Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. ( Benkov, KJ; Birnbaum, AH; Goldenberg, MM; Schechter, CB; See, MC, 2001) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 9.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "To verify whether a prolonged (therapeutic) treatment with ranitidine or famotidine may affect blood alcohol concentrations (BAC) in patients with duodenal ulcer (DU)." | 9.07 | Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. ( Bertol, E; Casini, A; Mari, F; Pizzigallo, AM; Surrenti, C, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 6.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "Famotidine cannot decrease the incidence of peptic ulcer or ulcer bleeding in thienopyridine users with atherosclerotic disease and a history of peptic ulcer." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| "The improvement in dysmotility-like dyspepsia symptom score on day 28 was significantly greater in the rabeprazole group (22." | 5.16 | Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. ( Amemoto, K; Ashida, K; Esaki, H; Fukuchi, T; Hashimoto, T; Isowa, G; Kiyota, K; Majima, K; Morikawa, H; Murotani, M; Ohyama, Y; Oka, H; Sakaguchi, M; Takao, F; Takao, M; Yamashita, H, 2012) |
| " We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin for vascular protection." | 5.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 5.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "Two hundred patients with duodenal ulcer were randomly divided into the treated group treated with JWC, 160 mg 3 times per day and the control group treated with famotidine 20 mg twice per day, both by orally taking before meal for 4 weeks, 100 cases in each group." | 5.12 | [Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer]. ( Chen, JX; Chen, JY; Ji, F, 2006) |
| "Omeprazole is more effective than famotidine for the control of gastro-oesophageal reflux disease symptoms in H." | 5.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "The aim of this study was to evaluate the effect of famotidine, a histamine receptor antagonist on corpus gastritis in patients with peptic ulcer disease." | 5.11 | Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. ( Chayama, K; Haruma, K; Hata, J; Ito, M; Kamada, T; Kawamura, Y; Kusunoki, H; Sugiu, K; Tanaka, S, 2005) |
| "Low-dose lansoprazole is more effective than full-dose famotidine for the control of symptoms in patients with gastro-oesophageal reflux disease, and H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "A total of 120 patients with peptic ulcer and non-ulcer dyspepsia were randomly assigned to a 2-week course of either: famotidine 40 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (FAT group; n = 60); or omeprazole 20 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (OAT group; n = 60)." | 5.09 | Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. ( Changchien, CS; Chen, JJ; Hsu, CC; Hu, TH; Lu, SN, 2001) |
| " pylori infection and duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were randomly assigned to a 1 week course of either famotidine 80 mg b." | 5.09 | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. ( Brandstätter, G; Dragosics, B; Gschwantler, M; Hentschel, E; Hirschl, AM; Klimpfinger, M; Oberhuber, G; Pasching, E; Schütze, K; Weiss, W; Wimmer, M; Wurzer, H, 1999) |
| " pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)." | 5.09 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000) |
| "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine." | 5.09 | Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. ( Benkov, KJ; Birnbaum, AH; Goldenberg, MM; Schechter, CB; See, MC, 2001) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 5.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "To verify whether a prolonged (therapeutic) treatment with ranitidine or famotidine may affect blood alcohol concentrations (BAC) in patients with duodenal ulcer (DU)." | 5.07 | Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. ( Bertol, E; Casini, A; Mari, F; Pizzigallo, AM; Surrenti, C, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| " pylori-positive and 10-negative subjects) with 100 mg aspirin plus 75 mg clopidogrel (AC) once-daily dosing and AC plus 20 mg famotidine twice-daily dosing (ACH)." | 2.79 | Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. ( Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2014) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 2.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| "Famotidine treatment including metronidazole-amoxicillin as second-line therapy provided a high eradication rate similar to lansoprazole therapy." | 2.72 | Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. ( Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K, 2006) |
| "Famotidine was administered after lunch and before sleep, and the others were after breakfast and dinner." | 2.71 | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. ( Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M, 2005) |
| "Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole." | 2.68 | Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. ( Andrews, P; Bae, H; Borody, TJ; Brandl, S; Fracchia, G; Shortis, NP, 1995) |
| "Diclofenac can cause gastric mucosal lesions, including ulcers, more easily than other NSAIDs." | 1.34 | Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. ( Fukui, H; Takakura, Y; Yajima, H; Yamao, J, 2007) |
| "Treatment with amoxicillin, metronidazole, and famotidine may not be effective in eradicating gastric infections with Helicobacter spp in dogs." | 1.30 | Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs. ( Cornetta, AM; Gleed, RD; McDonough, PL; Simpson, KW; Strauss-Ayali, D, 1998) |
| "Hyperemesis gravidarum is the most severe spectrum of gastrointestinal complaints in pregnant women." | 1.30 | Helicobacter pylori infection and persistent hyperemesis gravidarum. ( Jacoby, EB; Porter, KB, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (36.92) | 18.2507 |
| 2000's | 35 (53.85) | 29.6817 |
| 2010's | 5 (7.69) | 24.3611 |
| 2020's | 1 (1.54) | 2.80 |
| Authors | Studies |
|---|---|
| Ragab, MAA | 2 |
| Maher, HM | 2 |
| Tarek, S | 2 |
| Mahgoub, H | 2 |
| Uotani, T | 1 |
| Sugimoto, M | 4 |
| Nishino, M | 1 |
| Ichikawa, H | 1 |
| Sahara, S | 1 |
| Yamade, M | 1 |
| Iwaizumi, M | 1 |
| Yamada, T | 1 |
| Osawa, S | 1 |
| Sugimoto, K | 1 |
| Umemura, K | 1 |
| Watanabe, H | 1 |
| Miyajima, H | 2 |
| Furuta, T | 4 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Tsay, FW | 1 |
| Cheng, JS | 1 |
| Liu, CP | 1 |
| Lai, KH | 1 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Hawkey, CJ | 1 |
| Taha, AS | 1 |
| McCloskey, C | 1 |
| Prasad, R | 1 |
| Bezlyak, V | 1 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Lam, KF | 1 |
| Chu, WM | 1 |
| Chan, P | 1 |
| Ling, YH | 1 |
| Kng, C | 1 |
| Yuen, WC | 1 |
| Lau, YK | 1 |
| Kwan, A | 1 |
| Wong, BC | 1 |
| Murakami, K | 2 |
| Okimoto, T | 2 |
| Kodama, M | 2 |
| Tanahashi, J | 1 |
| Mizukami, K | 1 |
| Shuto, M | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Fujioka, T | 2 |
| Sakaguchi, M | 1 |
| Takao, M | 1 |
| Ohyama, Y | 1 |
| Oka, H | 1 |
| Yamashita, H | 1 |
| Fukuchi, T | 1 |
| Ashida, K | 1 |
| Murotani, M | 2 |
| Majima, K | 1 |
| Morikawa, H | 1 |
| Hashimoto, T | 2 |
| Kiyota, K | 1 |
| Esaki, H | 1 |
| Amemoto, K | 1 |
| Isowa, G | 1 |
| Takao, F | 1 |
| Mak, SK | 1 |
| Loo, CK | 1 |
| Wong, AM | 1 |
| Wong, PN | 1 |
| Lo, KY | 1 |
| Tong, GM | 1 |
| Lam, EK | 1 |
| Wong, AK | 1 |
| Adachi, K | 5 |
| Fujishiro, H | 3 |
| Mihara, T | 4 |
| Komazawa, Y | 4 |
| Kinoshita, Y | 5 |
| Ono, M | 2 |
| Kawamura, A | 1 |
| Liu, CC | 1 |
| Lee, CL | 1 |
| Chan, CC | 1 |
| Tu, TC | 1 |
| Liao, CC | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Kirika, NV | 1 |
| Bodrug, NI | 1 |
| Butorov, IV | 1 |
| Butorov, SI | 1 |
| Graham, DY | 1 |
| Opekun, AR | 1 |
| Jogi, M | 1 |
| Yamaoka, Y | 1 |
| Lu, H | 2 |
| Reddy, R | 1 |
| El-Zimaity, HM | 1 |
| Fujisawa, T | 1 |
| Azumi, T | 1 |
| Katsube, T | 1 |
| Furuta, K | 2 |
| Kazumori, H | 1 |
| Nomura, S | 1 |
| Suzuki, H | 2 |
| Masaoka, T | 1 |
| Kurabayashi, K | 1 |
| Ishii, H | 2 |
| Kitajima, M | 1 |
| Nomoto, K | 1 |
| Hibi, T | 2 |
| Okudaira, K | 2 |
| Shirai, N | 3 |
| Miura, S | 2 |
| Scarpignato, C | 1 |
| Fujiwara, Y | 1 |
| Higuchi, K | 1 |
| Nebiki, H | 1 |
| Chono, S | 1 |
| Uno, H | 1 |
| Kitada, K | 1 |
| Satoh, H | 1 |
| Nakagawa, K | 1 |
| Kobayashi, K | 1 |
| Tominaga, K | 1 |
| Watanabe, T | 1 |
| Oshitani, N | 1 |
| Arakawa, T | 1 |
| Kamada, T | 1 |
| Hata, J | 1 |
| Kusunoki, H | 1 |
| Sugiu, K | 1 |
| Ito, M | 1 |
| Tanaka, S | 1 |
| Kawamura, Y | 1 |
| Chayama, K | 1 |
| Haruma, K | 1 |
| Ishihara, S | 2 |
| Amano, Y | 1 |
| Hattori, S | 1 |
| Ji, F | 1 |
| Chen, JY | 1 |
| Chen, JX | 1 |
| Gon, S | 1 |
| Irie, Y | 1 |
| Takahashi, M | 1 |
| Sato, R | 1 |
| Inoue, K | 1 |
| Watanabe, K | 1 |
| Otsu, S | 1 |
| Ikuma, M | 1 |
| Hishida, A | 1 |
| Ishizaki, T | 1 |
| Fukuda, M | 2 |
| Shirasaka, D | 1 |
| Aoyama, N | 1 |
| Miki, I | 1 |
| Kachi, M | 1 |
| Morita, Y | 1 |
| Tamura, T | 1 |
| Kasuga, M | 1 |
| Spasov, AA | 1 |
| Chernikov, MV | 1 |
| Speranskaia, AS | 1 |
| Zaĭchenko, SI | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Yajima, H | 1 |
| Yamao, J | 1 |
| Fukui, H | 1 |
| Takakura, Y | 1 |
| Borody, TJ | 1 |
| Andrews, P | 1 |
| Fracchia, G | 1 |
| Brandl, S | 1 |
| Shortis, NP | 1 |
| Bae, H | 1 |
| Tsuji, S | 1 |
| Kawano, S | 1 |
| Higashi, T | 1 |
| Mukuda, T | 1 |
| Imaizumi, T | 1 |
| Tatsumi, T | 1 |
| Miura, N | 1 |
| Miyajima, K | 1 |
| Noguchi, M | 1 |
| Murakami, M | 1 |
| Saita, H | 1 |
| Takahashi, Y | 1 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 1 |
| Mizuno, M | 1 |
| Maeda, S | 1 |
| Gschwantler, M | 3 |
| Weiss, W | 3 |
| Penka, G | 1 |
| Zirm, B | 1 |
| Stupnicki, T | 1 |
| Spath, P | 1 |
| Sobhani, I | 1 |
| Chastang, C | 1 |
| De Korwin, JD | 1 |
| Lamouliatte, H | 1 |
| Mégraud, F | 1 |
| Guerre, J | 1 |
| Elouaer-Blanc, L | 1 |
| Dominguez, HL | 1 |
| Freston, JW | 1 |
| Parasakthi, N | 2 |
| Goh, KL | 3 |
| Lin, JT | 1 |
| Wang, JT | 1 |
| Wu, MS | 1 |
| Lee, WY | 1 |
| Yang, JC | 1 |
| Wang, TH | 1 |
| Casini, A | 1 |
| Pizzigallo, AM | 1 |
| Mari, F | 1 |
| Bertol, E | 1 |
| Surrenti, C | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| Sharma, MP | 1 |
| Navaratnam, P | 1 |
| Peh, SC | 1 |
| Wong, NW | 1 |
| Chuah, SY | 2 |
| Rahman, NA | 1 |
| Lo, YL | 1 |
| Gladziwa, U | 1 |
| Klotz, U | 1 |
| Moayyedi, P | 1 |
| Toetsch, M | 1 |
| Suzuki, M | 1 |
| Mori, M | 1 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Dogăn, UB | 1 |
| Tunçer, C | 1 |
| Dursun, A | 1 |
| Kandilci, U | 1 |
| Das, UN | 1 |
| Cornetta, AM | 1 |
| Simpson, KW | 1 |
| Strauss-Ayali, D | 1 |
| McDonough, PL | 1 |
| Gleed, RD | 1 |
| Dragosics, B | 2 |
| Wurzer, H | 2 |
| Brandstätter, G | 2 |
| Kanayama, S | 1 |
| Jacoby, EB | 1 |
| Porter, KB | 1 |
| Sugano, K | 2 |
| Sasakii, M | 1 |
| Joh, T | 1 |
| Yokoyama, Y | 1 |
| Seno, K | 1 |
| Tsuchida, K | 1 |
| Kurokawa, T | 1 |
| Itoh, M | 1 |
| Schütze, K | 1 |
| Hirschl, AM | 1 |
| Pasching, E | 1 |
| Wimmer, M | 1 |
| Klimpfinger, M | 1 |
| Oberhuber, G | 1 |
| Hentschel, E | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Yoshida, N | 1 |
| Yoshikawa, T | 1 |
| Tanaka, Y | 1 |
| Fujita, N | 1 |
| Kassai, K | 1 |
| Naito, Y | 1 |
| Kondo, M | 1 |
| Mansurova, FKh | 1 |
| Kadyrov, DM | 1 |
| Odinaev, RI | 1 |
| Ishankulova, DM | 1 |
| Icatlo, FC | 1 |
| Kimura, N | 1 |
| Goshima, H | 1 |
| Kodama, Y | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Yamamoto, S | 1 |
| Matsumura, N | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Sasaki, N | 1 |
| Taniyama, K | 1 |
| Liu, WZ | 1 |
| Xiao, SD | 1 |
| Hu, PJ | 1 |
| Cui, Y | 1 |
| Tytgat, GN | 1 |
| See, MC | 1 |
| Birnbaum, AH | 1 |
| Schechter, CB | 1 |
| Goldenberg, MM | 1 |
| Benkov, KJ | 1 |
| Radwan, P | 1 |
| Grodzieński, R | 1 |
| Zaorska-Rajca, J | 1 |
| Skrzydło-Radomańska, B | 1 |
| Słomka, M | 1 |
| Wysokiński, A | 1 |
| Hsu, CC | 1 |
| Chen, JJ | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Changchien, CS | 1 |
| Mutoh, H | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Kawauchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
5 reviews available for famotidine and Helicobacter Infections
| Article | Year |
|---|---|
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2005 |
Hypothesis: cis-unsaturated fatty acids as potential anti-peptic ulcer drugs.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Fatty Acids, Unsaturated; Helicobacter Infections; He | 1998 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 1999 |
[Duodenal ulcer].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; | 2002 |
39 trials available for famotidine and Helicobacter Infections
| Article | Year |
|---|---|
Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Topics: Adult; Anti-Ulcer Agents; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy | 2014 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me | 2009 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.
Topics: Aged; Alcohol Drinking; Anti-Ulcer Agents; Drug Administration Schedule; Famotidine; Female; Helicob | 2011 |
Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzamides; Dyspepsia; Esop | 2012 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Nega | 2003 |
Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
Topics: Adult; Biomarkers; Cross-Over Studies; Drug Tolerance; Famotidine; Gastric Acidity Determination; Ga | 2003 |
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Breath Tests; Carbolines; Clarithromycin; Drug Therapy, Co | 2003 |
[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug | 2004 |
Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists.
Topics: Acetamides; Adult; Ambulatory Care; Circadian Rhythm; Cross-Over Studies; Cross-Sectional Studies; D | 2004 |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2005 |
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacte | 2005 |
Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Ulcer Agents; Famotidine; Female; Gastric Acid; Gastritis; H | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
[Comparative study on Jinghua Weikang Capsule and famotidine in treating duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Duoden | 2006 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Topics: Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C1 | 2006 |
No significant difference in neutrophil activation found among three H2RAs.
Topics: Acetamides; Adult; Dyspepsia; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Hist | 2007 |
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Famotidine; F | 1995 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Fa | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Eradication of Helicobacter pylori by a combination of amoxicillin and famotidine.
Topics: Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastritis; Helicobacter | 1995 |
Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Fema | 1995 |
Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia.
Topics: Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Famotidine; Helicobacter Infe | 1995 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicoba | 1994 |
Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer.
Topics: Adult; Alcohol Dehydrogenase; Duodenal Ulcer; Ethanol; Famotidine; Helicobacter Infections; Helicoba | 1994 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori--a randomized, double-blind comparison of a three times daily and twice daily regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antitrichomonal Agents; Double-Blind Method; Drug Resistance, | 1997 |
Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Famotidi | 1998 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicob | 1999 |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resis | 1999 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact | 2000 |
A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug Therapy, C | 2000 |
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
Topics: Abdominal Pain; Adolescent; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; Double-Blind M | 2001 |
[The effect of prokinetic treatment and eradication of Helicobacter pylori on gastric emptying and symptoms of functional dyspepsia].
Topics: Adolescent; Adult; Cisapride; Drug Therapy, Combination; Dyspepsia; Famotidine; Female; Gastric Empt | 2001 |
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2001 |
21 other studies available for famotidine and Helicobacter Infections
| Article | Year |
|---|---|
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
NSAIDs and aspirin: notorious or FAMOUS?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Esop | 2009 |
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 2002 |
False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH.
Topics: Adolescent; Adult; Aged; Biopsy; Breath Tests; Citric Acid; Endoscopy, Gastrointestinal; False Negat | 2004 |
Effect of dietary anti-urease immunoglobulin Y on Helicobacter pylori infection in Mongolian gerbils.
Topics: Animals; Anti-Ulcer Agents; Diet; Disease Models, Animal; Famotidine; Gastric Mucosa; Gerbillinae; H | 2005 |
Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2006 |
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
Topics: Animals; Disease Models, Animal; Famotidine; Female; Gastric Mucosa; Helicobacter Infections; Histam | 2005 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Bone Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; End | 2007 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
Adenylate cyclase of gastric mucosa in patients with chronic renal failure.
Topics: Adenylyl Cyclases; Anti-Ulcer Agents; Cyclic AMP; Famotidine; Female; Gastric Mucosa; Gastrins; Heli | 1996 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
Effect of chronic acid inhibition on duodenal bulb gastric metaplasia and Helicobacter pylori.
Topics: Adult; Case-Control Studies; Duodenal Ulcer; Duodenum; Famotidine; Female; Gastric Mucosa; Helicobac | 1998 |
Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Carbon Isotope | 1998 |
Helicobacter pylori infection and persistent hyperemesis gravidarum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Famotidine | 1999 |
Optimum management of mild esophagitis in Japan.
Topics: Anti-Ulcer Agents; Disease Management; Esophagitis, Peptic; Famotidine; Helicobacter Infections; Hel | 1999 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cel | 2000 |
[Quamatel application in three-drug eradication therapy of duodenal ulcer and gastroduodenal ulcerations associated with helicobacter pylori infection].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Fa | 2000 |
Enhanced reduction of Helicobacter pylori load in precolonized mice treated with combined famotidine and urease-binding polysaccharides.
Topics: Animals; Anticoagulants; Dextran Sulfate; Disease Models, Animal; Drug Therapy, Combination; Famotid | 2000 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |